Clinical Trial Update: A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of necitumumab and pembrolizumab in stage IV non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Necitumumab (necitumumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Stage IV Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-10-05